

Merck -Suvorexant delayed but no additional studies required is a sigh of relief

https://marketpublishers.com/r/M0D854D3BF5EN.html

Date: July 2013

Pages: 1

Price: US\$ 90.00 (Single User License)

ID: M0D854D3BF5EN

Abstracts

FDA recently issued a complete response letter to MRK's Suvorexant. As per the complete response letter, the USFDA will need manufacturing data on the 10mg dose and clinical data for the 5mg dose. Due to safety concerns; the higher doses (30mg and 40mg) would not be approved. We see the launch timelines delayed by atleast 12 to 18 months. In case of the 10mg dose Merck would have to conduct an additional stability study, which would take atleast 6 months. For the 5mg dose, there would be additional clinical studies that would be required, for which we believe PK/PD studies should suffice.



I would like to order

Product name: Merck -Suvorexant delayed but no additional studies required is a sigh of relief

Product link: https://marketpublishers.com/r/M0D854D3BF5EN.html

Price: US\$ 90.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/M0D854D3BF5EN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:	
Last name:	
Email:	
Company:	
Address:	
City:	
Zip code:	
Country:	
Tel:	
Fax:	
Your message:	
	**All fields are required
	Custumer signature

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970